GVHO (Netherlands): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What GVHO is
Origin and authorising body. Netherlands, under the Geneesmiddelenwet (Dutch Medicines Act) and the Regeling Geneesmiddelenwet. The authorising body for each individual case is the College ter Beoordeling van Geneesmiddelen (CBG, Medicines Evaluation Board) and Inspectie Gezondheidszorg en Jeugd (IGJ, Health and Youth Care Inspectorate), acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. The Dutch framework operates under the Geneesmiddelenwet (Medicines Act) and the Regeling Geneesmiddelenwet. Article 40 of the Geneesmiddelenwet establishes provisions for medicines not registered in the Netherlands, including the artsenverklaring procedure for individual-patient supply. The CBG handles registration and scientific assessment; the IGJ handles supply-chain compliance and pharmacy oversight.
The Dutch artsenverklaring framework is the operational architecture under which Dutch physicians prescribe and dispense medicines that are not registered in the Netherlands or not registered in the patient's indication. The treating physician issues a declaration confirming clinical necessity, the dispensing pharmacy obtains the medicine from a licensed wholesaler or import partner, and IGJ audits the supply chain rather than pre-authorising each case. The framework is the closest Dutch equivalent to the UK Individual Patient Supply and German Einzelimport routes.
The Netherlands has well-developed specialty pharmacy infrastructure and a regulator (IGJ) that operates pragmatically with hospital pharmacies and import partners. Major Dutch academic centres (UMC Utrecht, Amsterdam UMC including AMC and VUmc sites, Erasmus MC Rotterdam, Radboud Nijmegen, LUMC Leiden, Maastricht UMC) handle the majority of named-patient and compassionate-use cases. The framework's audit-rather-than-pre-authorise structure makes it among the operationally fastest in Europe for routine cases.
This page consolidates Reserve Meds's operational view of the GVHO (Netherlands) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each GVHO (Netherlands)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use GVHO
The Dutch framework is used by Dutch-licensed prescribers on behalf of patients in the Netherlands. Cross-border patients cannot directly use the framework; the existence of Dutch precedents is useful for destination-country regulators considering parallel programmes.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under GVHO
Specialty oncology agents, rare-disease biologics, advanced therapy medicinal products, paediatric extensions of adult-approved medicines, and post-approval indications not yet through Dutch registration.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a GVHO (Netherlands) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the GVHO (Netherlands) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts GVHO (Netherlands) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a GVHO (Netherlands) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts GVHO (Netherlands) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept GVHO (Netherlands) authorisation as the legal basis for import but does recognise a GVHO (Netherlands) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A GVHO application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Treating physician's artsenverklaring (declaration of clinical necessity).
- Patient identifier and clinical history.
- Dispensing pharmacy authorisation.
- Informed consent.
- Chain-of-custody documentation.
- Manufacturer or wholesaler supply confirmation.
Typical timeline
Routine artsenverklaring cases complete in 1 to 4 weeks. Imported specialty cases: 4 to 8 weeks.
Costs and reimbursement
Dutch statutory health insurance (zorgverzekering) may cover artsenverklaring medicines depending on indication; this is decided case by case. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For GVHO (Netherlands) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the GVHO (Netherlands) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.